First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known. We assessed the efficacy and safety of ceritinib versus platinum-based chemotherapy in these patients.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet

Title: Lancet (London, England)

Publisher: Elsevier BV

ISSN (Electronic): 1474-547X

ISSN (Print): 0140-6736

Publication date (Electronic): March 04 2017

Volume: 389

Issue: 10072

Affiliations

[1 ] University Paris-Sud, Orsay, France; Institut Gustave Roussy, Villejuif, France. Electronic address: Jean-Charles.Soria@gustaveroussy.fr.

[2 ] National Cancer Centre Singapore and Genome Institute of Singapore, Singapore.

[3 ] Azienda Ospedale Perugia, Perugia, Italy.

[4 ] Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.

[5 ] University Hospital Virgen del RocioDoce de Octubre, Universidad Complutense & CNIO, Madrid, Spain.

[6 ] University Hospital Cologne, Cologne, Germany.

[7 ] Songklanagarind Hospital, Songkla, Thailand.

[8 ] State Pavlov Medical University, St Petersburg, Russia.

[9 ] Az. Ospedaliera San Gerardo, Monza, Italy.

[10 ] National Taiwan University Hospital, Taipei, Taiwan.

[11 ] Respiratory Oncology Unit, Department of Respiratory and Critical Care Medicine, Otto-Wagner-Spital, Vienna, Austria.

[12 ] CHU de LILLE, Lille, France.

[13 ] Taipei Veterans General Hospital, Taipei, Taiwan.

[14 ] Hôpital Albert Michallon, Grenoble, France.

[15 ] University Hospital A Coruña, La Coruna, Spain.

[16 ] Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

[17 ] Novartis Pharma AG, Basel, Switzerland.

[18 ] Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.

Article

Publisher Item ID: S0140-6736(17)30123-X

DOI: 10.1016/S0140-6736(17)30123-X

PubMed ID: 28126333

SO-VID: bb0d9166-6b3b-4ee5-a20b-31828c6a4f56

History

Data availability:

Comments

Comment on this article

scite_

Cited by 405

See all cited by

- Version 1